Needham Downgrades Surmodics to Hold
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has downgraded Surmodics (NASDAQ:SRDX) from Buy to Hold.

May 29, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Needham analyst Mike Matson has downgraded Surmodics from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on Surmodics' short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100